8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Current legal status of compounded liraglutide in the US, including FDA shortage determinations, 503A/503B pharmacy rules, Novo Nordisk patent timelines, and generic availability after Victoza exclusivity ended.
A detailed comparison of how the FDA and EMA evaluated, approved, and regulate liraglutide (Victoza, Saxenda), covering label differences, post-market surveillance, and safety signals.
A clinical review of liraglutide safety signals reported through the FDA Adverse Event Reporting System (FAERS), including pancreatitis, gallbladder events, thyroid concerns, and acute kidney injury.
Full FDA approval history for liraglutide (Victoza, Saxenda), covering every indication, label expansion, boxed warning, post-market safety update, and generic entry from 2010 through 2025.
A complete guide to liraglutide's regulatory history across the FDA, EMA, and other agencies, including approved indications, label requirements, boxed warnings, and post-market surveillance findings.
A complete, physician-reviewed guide to every liraglutide (Victoza, Saxenda) label update from 2020 through 2026, including new safety warnings, dosing revisions, and post-market surveillance findings.
A complete clinical and regulatory guide to liraglutide's patent field, FDA approval history, prescribing label, and post-market safety record, reviewed by the HealthRX.com medical team.
A clinical review of liraglutide's regulatory history, current FDA label, generic pipeline status, and next-generation GLP-1 receptor agonists positioned to follow it.